NCT05011019

A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis

Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis (Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors)

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

AL2846 is a multi-target receptor tyrosine kinase inhibitor. The purpose of this study is to evaluate the safety and efficacy of AL2846 capsules in Chinese patients with type I neurofibromatosis (NF1) (neurofibromas and malignant peripheral nerve sheath tumors).

Conditions

• Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors

Interventions

Type	Name	Description
DRUG	AL2846 capsules	AL2846 is a multi-target receptor tyrosine kinase inhibitor.

Timeline

• Start date: 2021-09-07
• Primary completion: 2024-02-02
• Completion: 2024-02-02
• First posted: 2021-08-18
• Last updated: 2024-03-21

Locations

1 site across 1 country: China